Amyloid

Oncology·MeSH: Immunoglobulin Light-chain Amyloidosis

Prevalence

5.0 / 100K

54 drugs in development·27 companies·2 clinical trials

Drug Pipeline by Phase

Approved(12)

Drug	Company
Amvuttra	Royalty Pharma plc (RPRX)
AMVUTTRA	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
attruby	BridgeBio Pharma, Inc. (BBIO)
Attruby / Beyonttra (acoramidis)	BridgeBio Pharma, Inc. (BBIO)
Kisunla	ELI LILLY & Co (LLY)
neuraceq	Lantheus Holdings, Inc. (LNTH)
ONPATTRO	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
supplemental new drug	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
tegsedi	AKCEA THERAPEUTICS, INC. (AKCA)
Tegsedi	PTC THERAPEUTICS, INC. (PTCT)
vizamyl	GE HealthCare Technologies Inc. (GEHC)
wainua	ASTRAZENECA PLC (AZN)

Phase 3(16)

Drug	Company
acoramidis	Eidos Therapeutics, Inc. (EIDX)
acoramidis (AG10)	BridgeBio Pharma, Inc. (BBIO)
alxn2060	ALEXION PHARMACEUTICALS, INC. (ALXN)
alxn2220	Hepion Pharmaceuticals, Inc. (CTRVP)
Birtamimab	PROTHENA CORP PUBLIC LTD CO (PRTA)
cael-101	ALEXION PHARMACEUTICALS, INC. (ALXN)
cael-101	Fortress Biotech Inc. (FBIO)
CAEL-101	ARS Pharmaceuticals, Inc. (SPRY)
eplontersen	IONIS PHARMACEUTICALS INC (IONS)
eplontersen	ASTRAZENECA PLC (AZN)
ixazomib	X4 Pharmaceuticals, Inc (XFOR)
nnc6019-0001	Novo Nordisk A/S (NVO)
NNC6019-0001	PROTHENA CORP PUBLIC LTD CO (PRTA)
Nucresiran	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Patisiran	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Vutrisiran	ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Phase 2(7)

Drug	Company
ALN-APP	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
alxn2220	ASTRAZENECA PLC (AZN)
Daratumumab	FATE THERAPEUTICS INC (FATE)
Daratumumab SC	FATE THERAPEUTICS INC (FATE)
NNC6019	PROTHENA CORP PUBLIC LTD CO (PRTA)
Pomalidomide	FATE THERAPEUTICS INC (FATE)
sabirnetug (ACU193)	Acumen Pharmaceuticals, Inc. (ABOS)

Phase 1(6)

Drug	Company
ALN-TTRSC04	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
coramitug	Novo Nordisk A/S (NVO)
Isatuximab	Merus N.V. (MRUS)
Ixazomib	FATE THERAPEUTICS INC (FATE)
NTLA-2001	Intellia Therapeutics, Inc. (NTLA)
nxc-201	Immix Biopharma, Inc. (IMMX)

Preclinical(1)

Drug	Company
ag10	ALEXION PHARMACEUTICALS, INC. (ALXN)

Unknown(2)

Drug	Company
amputee garment for use with lympha press optimal plus	AC Immune SA (ACIU)
inotersen	AKCEA THERAPEUTICS, INC. (AKCA)

Phase 1/Phase 2(8)

Drug	Company
aci-24.060 at dose a in study part 1a	AC Immune SA (ACIU)
aci-24.060 at dose a in study part 2	AC Immune SA (ACIU)
aci-24.060 at dose b in study part 1a	AC Immune SA (ACIU)
aci-24.060 at dose b in study part 2	AC Immune SA (ACIU)
aci-24.060 at dose c in study part 1a	AC Immune SA (ACIU)
aci-24.060 at dose c in study part 2	AC Immune SA (ACIU)
azd0120	ALEXION PHARMACEUTICALS, INC. (ALXN)
nxc-201 car-t	Axcella Health Inc. (AXLA)

Phase 4(2)

Drug	Company
Isatuximab	Filana Therapeutics Inc. (FLNA)
ixazomib	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

BioSniper tracks 54 drugs in development for Amyloid across 27 companies.

There are 2 clinical trials targeting Amyloid tracked by BioSniper.

The estimated prevalence of Amyloid is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.